Passage Bio, Inc. (PASG)
| Market Cap | 712.50M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -133.53M |
| Shares Out | 53.98M |
| EPS (ttm) | -2.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $12.30 |
| Previous Close | $13.20 |
| Change ($) | -0.90 |
| Change (%) | -6.82% |
| Day's Open | 13.24 |
| Day's Range | 12.26 - 13.43 |
| Day's Volume | 263,865 |
| 52-Week Range | 11.67 - 30.87 |
Chief Commercial Officer, Chief Financial Officer and Chief Medical Officer to focus on driving company growth and advancing robust pipeline of transformative therapies for patients with CNS disorders C...
Passage Bio (NASDAQ: PASG) shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $29 price target. The firm said the company's gene ther...
PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central ne...
PHILADELPHIA, May 11, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nerv...
Focus to be on frontotemporal dementia with granulin mutations Focus to be on frontotemporal dementia with granulin mutations
PHILADELPHIA, May 05, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central ner...
PHILADELPHIA, April 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system d...
- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options
Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company –
PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system d...
PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (C...
FDA designation will facilitate development and expedited review of company's lead gene therapy product candidates for life-threatening diseases with unmet medical needs: PBGM01 for GM1 gangliosidosis (...
- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe...
PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system d...
PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...
PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (C...
- Phase 1/2 trial expected to commence in first half of 2021
Passage Bio Inc (NASDAQ: PASG) is leveraging the UPenn Gene Therapy Program to access compelling translational research and develop a range of differentiated adeno-associated virus gene therapies for ra...
– Second Product Candidate Expected to Enter Clinic in First Half of 2021
A secondary offering will dilute shareholders.
PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system dis...
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system dis...
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and M...
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...
FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021
- Company invests to build in-house capabilities to support advancement of pipeline -
- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program -
- Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical trials to comm...
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...
Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University's research, which has the potential to significantly advance nascent field of gene ...
PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...
Passage Bio, Inc. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript
– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 – – Phase 1/2 clinical trials for FTD-GRN and Krabbe expected to init...
Genetic testing, educational materials and counseling offered at no charge to patients Genetic testing, educational materials and counseling offered at no charge to patients
PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...
PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...
PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...
Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
About PASG
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAV... [Read more...]
| Industry Biotechnology | IPO Date Feb 28, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol PASG |
Analyst Forecasts
According to 7 analysts, the average rating for Passage Bio stock is "Strong Buy." The 12-month stock price forecast is 29.71, which is an increase of 141.54% from the latest price.